Findings

What do systematic reviews say?

48 questions · 49 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 14 · 28.6%GRADE not reported 10 · 20.4%Very low 3 · 6.1%Low 22 · 44.9%Moderate 0 · 0%High 0 · 0%

Methotrexate vs placebo

Withdrawals due to adverse events · children and young people with JIA

Methotrexate showed no clear difference in withdrawals due to adverse events (up to 6 months) compared with placebo (low certainty).

1 finding from 1 review

Methotrexate for juvenile idiopathic arthritis 2024 · Cochrane Headline outcomes only
RR 3.46 [0.6, 19.79]
3 studies · 328 participants
Low

Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone

OutcomesTime frame of absolute effects · children and young people with JIA

The review found no eligible studies for this question.

1 finding from 1 review

Methotrexate for juvenile idiopathic arthritis 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Proportion of participants with success, defined as 0 to trace cells or 2‐step decrease in activity SUN‐grading ( · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old

The intervention showed no clear difference in proportion of participants with success, defined as 0 to trace cells… (low certainty).

1 finding from 1 review

Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis‐associated uveitis 2022 · Cochrane Headline outcomes only
RR 0.66 [0.21, 2.1]
2 studies · 43 participants
Low

Intervention not reported

Risk of failure defined as 2‐step increase in activity in SUN grading ( · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old

The intervention showed no clear difference in risk of failure defined as 2‐step increase in activity in SUN… (low certainty).

1 finding from 1 review

Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis‐associated uveitis 2022 · Cochrane Headline outcomes only
RR 0.31 [0.01, 7.15]
1 study · 31 participants
Low

Intervention not reported

Risk of recurrence and mean time‐to‐recurrence after induction of remission at 2 or 6 months · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old

1 finding from 1 review

Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis‐associated uveitis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Intervention not reported

Mean change from baseline in logMAR visual acuity at 6 months*2 · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old

1 finding from 1 review

Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis‐associated uveitis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 90 participants
Low

Intervention not reported

Mean change from baseline in number of topical or systemic steroids at 6 months*2 · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old

1 finding from 1 review

Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis‐associated uveitis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Intervention not reported

Frequency and nature of adverse effects · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old

1 finding from 1 review

Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis‐associated uveitis 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 134 participants
Low